Iclusig
Ended Awarded Last action
- Contract number
- 36C26019N0104
- Awardee
-
Ariad Pharmaceuticals, Inc. UEI EVMMLCKBZS47 Part of Takeda Pharmaceutical Company LIMITED
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $253,048
Award facts
- Contract value 100% obligated
- $253,048.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Cambridge, MA 02139, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$57,511 | |
| Funding Only Action | -$138,026 | |
| Original award | $448,586 |
About this award
This federal contract award was made by the Department of Veterans Affairs (VA) Veterans Health Administration to Ariad Pharmaceuticals, Inc., a subsidiary of the Japanese pharmaceutical company Takeda Pharmaceutical Company Limited. The contract, valued at $253,048.40, is for the delivery of the cancer drug Iclusig (ponatinib) under the GSA Pharmaceuticals and Drugs schedule. Ariad, as a prime contractor, has previously received orders from the VA to supply other oncology medications such as Lenvima (lenvatinib) to veterans hospitals and medical centers. This contract was not set aside and was awarded on a firm fixed-price basis. The place of performance is in Cambridge, MA.
Quick answers
Who was awarded contract 36C26019N0104?
36C26019N0104 was awarded to Ariad Pharmaceuticals, Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on October 1, 2018.
How much is contract 36C26019N0104 worth?
The government has obligated $253,048 on 36C26019N0104.
Is contract 36C26019N0104 an order under another contract?
Yes. 36C26019N0104 is a BPA call under V797D50395-VA797P15A0016, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26019N0104 competed?
The extent of competition for 36C26019N0104 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award